Increasing the Therapeutic Ratio of Radiotherapy (Запис № 448485)

МАРК-запис
000 -LEADER
fixed length control field 05285nam a22006015i 4500
001 - CONTROL NUMBER
control field 978-3-319-40854-5
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20210118133219.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 161121s2017 gw | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9783319408545
-- 978-3-319-40854-5
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-3-319-40854-5
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED062000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJCL
Source thema
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
245 10 - TITLE STATEMENT
Title Increasing the Therapeutic Ratio of Radiotherapy
Medium [electronic resource] /
Statement of responsibility, etc edited by Philip J. Tofilon, Kevin Camphausen.
250 ## - EDITION STATEMENT
Edition statement 1st ed. 2017.
264 #1 -
-- Cham :
-- Springer International Publishing :
-- Imprint: Humana,
-- 2017.
300 ## - PHYSICAL DESCRIPTION
Extent VIII, 280 p. 41 illus., 34 illus. in color.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement Cancer Drug Discovery and Development,
Міжнародний стандартний серійний номер для назви серії (ISSN) 2196-9906
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Part 1. Molecular Targets -- 1. Improving the therapeutic ratio of radiotherapy by targeting the DNA Damage Response -- 2. Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity -- 3. Histone Deacetylase Inhibitors and Tumor Radiosensitization -- 4. Radioprotection as a Method to Enhance the Therapeutic Ratio of Radiotherapy -- Part 2. Microenvironment -- 5. Application of Functional Molecular Imaging in Radiation Oncology -- 6. Remodeling the Irradiated Tumor Microenvironment: The 5th R of Radiobiology? -- 7. Combining Radiotherapy and Immunotherapy: Emerging Preclinical Observations of Lymphocyte Costimulatory and Inhibitory Receptor Modulation -- Part 3. Clinical -- 8. Stereotactic Body Radiation Therapy (SBRT) or Alternative Fractionation Schedules -- 9. Novel Imaging for Treatment Planning or Tumor Response -- 10. Increasing the Therapeutic Efficacy of Radiotherapy Using Nanoparticles -- Index.
520 ## - SUMMARY, ETC.
Summary, etc Current cancer therapies are focused on three general strategies: modifying intrinsic radiosensitivity via molecular targeting, manipulating microenvironmental factors to enhance tumor susceptibility to radiation, and improving delivery of radiation to critical tumor locations while sparing normal tissues. The goal of this volume is to describe a number of promising approaches corresponding to each strategy. In general, research in radiation oncology tends to be siloed into fundamental biology, physics or treatment delivery. The strategies for improving therapeutic ratio encompassed in this book will involve each of these components of radiation oncology. Thus, they will illustrate the variety of disparate approaches available for potentially improving the efficacy of radiotherapy, which may then stimulate discussion across disciplines and foster further translational investigations. Although a goal of each chapter will be to highlight advances within an approach, of equal importance will be the delineation of barriers to successful clinical application and how to overcome or minimize such impediments. Along these lines, because therapeutic ratio incorporates both tumor and normal tissue radio response, a point of emphasis will be the mechanistic rationale for selectively modifying tumor (sensitization) or normal cells (protection). Finally, whereas the literature is replete with studies describing potential targets/strategies for increasing the therapeutic ratio for radiotherapy, this book will focus on those supported by in vivo data consistent with impending translational application along with those that are already being evaluated in the clinic.
506 ## - RESTRICTIONS ON ACCESS NOTE
Terms governing access Available to subscribing member institutions only. Доступно лише організаціям членам підписки.
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Online access from local network of NaUOA.
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Online access with authorization at https://link.springer.com/
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Онлайн-доступ з локальної мережі НаУОА.
506 ## - RESTRICTIONS ON ACCESS NOTE
Standardized terminology for access restriction Онлайн доступ з авторизацією на https://link.springer.com/
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer research.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Radiotherapy.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug resistance.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cancer Research.
-- http://scigraph.springernature.com/things/product-market-codes/B11001
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Radiotherapy.
-- http://scigraph.springernature.com/things/product-market-codes/H29056
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug Resistance.
-- http://scigraph.springernature.com/things/product-market-codes/B16020
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Tofilon, Philip J.
Relator term editor.
Relator code edt
-- http://id.loc.gov/vocabulary/relators/edt
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Camphausen, Kevin.
Relator term editor.
Relator code edt
-- http://id.loc.gov/vocabulary/relators/edt
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9783319408521
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9783319408538
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9783319822013
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer Drug Discovery and Development,
-- 2196-9906
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1007/978-3-319-40854-5">https://doi.org/10.1007/978-3-319-40854-5</a>
912 ## -
-- ZDB-2-SME
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type ЕКнига

Немає доступних примірників.